2024
Outcomes of repeat conventional transarterial chemoembolization in patients with liver metastases
Ghabili K, Windham-Herman A, Konstantinidis M, Murali N, Borde T, Adam L, Laage-Gaupp F, Lin M, Chapiro J, Georgiades C, Nezami N. Outcomes of repeat conventional transarterial chemoembolization in patients with liver metastases. Annals Of Hepatology 2024, 29: 101529. PMID: 39033928, PMCID: PMC11558520, DOI: 10.1016/j.aohep.2024.101529.Peer-Reviewed Original ResearchConventional transarterial chemoembolizationLiver metastasesNeuroendocrine tumorsColorectal carcinomaTransarterial chemoembolizationOverall survivalLung cancerAssociated with improved patient survivalManagement of liver metastasesMetastatic liver lesionsSingle-institution analysisNonresponding patientsSurvival outcomesPatient survivalResponse assessmentTarget lesionsMetastasisLiver lesionsPatientsResponse rateChemoembolizationSurvivalLiverLesionsCancer
2020
Automated feature quantification of Lipiodol as imaging biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer
Stark S, Wang C, Savic LJ, Letzen B, Schobert I, Miszczuk M, Murali N, Oestmann P, Gebauer B, Lin M, Duncan J, Schlachter T, Chapiro J. Automated feature quantification of Lipiodol as imaging biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer. Scientific Reports 2020, 10: 18026. PMID: 33093524, PMCID: PMC7582153, DOI: 10.1038/s41598-020-75120-7.Peer-Reviewed Original ResearchConceptsConventional transarterial chemoembolizationLipiodol depositionTransarterial chemoembolizationLiver cancerPeripheral depositionLipiodol depositsTherapeutic efficacyNecrotic tumor areasBaseline MRITherapy optionsTumor responseTreatment responseTumor volumeLiver lesionsLipiodolH postTumor areaH-CTHounsfield unitsBiomarkersChemoembolizationHigh rateTumorsCancerImproved responseLipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer
Miszczuk MA, Chapiro J, Geschwind JH, Thakur V, Nezami N, Laage-Gaupp F, Kulon M, van Breugel JMM, Fereydooni A, Lin M, Savic LJ, Tegel B, Wahlin T, Funai E, Schlachter T. Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer. Translational Oncology 2020, 13: 100742. PMID: 32092672, PMCID: PMC7036424, DOI: 10.1016/j.tranon.2020.01.003.Peer-Reviewed Original Research
2019
Immunotherapy and the Interventional Oncologist: Challenges and Opportunities—A Society of Interventional Oncology White Paper
Erinjeri JP, Fine GC, Adema GJ, Ahmed M, Chapiro J, den Brok M, Duran R, Hunt SJ, Johnson DT, Ricke J, Sze DY, Toskich BB, Wood BJ, Woodrum D, Goldberg SN. Immunotherapy and the Interventional Oncologist: Challenges and Opportunities—A Society of Interventional Oncology White Paper. Radiology 2019, 292: 25-34. PMID: 31012818, PMCID: PMC6604797, DOI: 10.1148/radiol.2019182326.Peer-Reviewed Original ResearchConceptsInterventional oncologyCancer management planCancer-related problemsInterventional oncologistsTreatment of cancerCancer patientsImmuno-oncologyInvasive proceduresInterventional radiologyRadiation oncologyOncologyImage guidanceCancerCancer researchSubspecialty fieldsPivotal roleImmunotherapyPatientsOncologistsDiagnosisCare
2015
Targeting glucose metabolism in cancer: a new class of agents for loco-regional and systemic therapy of liver cancer and beyond?
Savic LJ, Chapiro J, Duwe G, Geschwind J. Targeting glucose metabolism in cancer: a new class of agents for loco-regional and systemic therapy of liver cancer and beyond? Hepatic Oncology 2015, 3: 19-28. PMID: 26989470, PMCID: PMC4792180, DOI: 10.2217/hep.15.36.Peer-Reviewed Original ResearchIntra-arterial therapyHepatocellular carcinomaCancer-related deathUnresectable diseaseCancer cell metabolismSystemic therapyTherapeutic optionsTumor controlPrevalent cancerLiver cancerGlucose metabolismAntiglycolytic agentsTumor growthSystemic toxicitySelective anticancer therapyTherapyAnticancer therapyCancerNew targetsWarburg effectMolecular featuresAntiglycolytic drugsCell metabolismDelivery methodsMetabolismSystematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions
Duran R, Chapiro J, Schernthaner RE, Geschwind JF. Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions. British Journal Of Radiology 2015, 88: 20140564. PMID: 25978585, PMCID: PMC4651391, DOI: 10.1259/bjr.20140564.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntineoplastic AgentsCarcinoma, HepatocellularCatheter AblationChemoembolization, TherapeuticCombined Modality TherapyDiffusion of InnovationEmbolization, TherapeuticFemaleForecastingHumansInfusions, Intra-ArterialLiver NeoplasmsMaleMicrospheresNiacinamidePatient SelectionPhenylurea CompoundsRadiopharmaceuticalsSorafenibYttrium RadioisotopesConceptsIntra-arterial therapyHepatocellular carcinomaSecondary liver malignanciesManagement of patientsHealthy liver tissueLocoregional therapyLiver malignanciesClinical rationaleHigh doseInterventional oncologySystematic reviewAnticancer treatmentLiver tissueInvasive natureClinical achievementsChemoresistant cancersTherapyMedical communityPatientsCarcinomaTreatmentPivotal roleMalignancySorafenibCancer
2013
Intraarterial therapies for primary liver cancer: state of the art
Chapiro J, Tacher V, Geschwind JF. Intraarterial therapies for primary liver cancer: state of the art. Expert Review Of Anticancer Therapy 2013, 13: 1157-1167. PMID: 24099626, DOI: 10.1586/14737140.2013.845528.Peer-Reviewed Original ResearchConceptsPrimary liver cancerTreatment of patientsIntraarterial therapyHepatocellular carcinomaLiver cancerIntermediate-stage diseaseOfficial treatment guidelinesAvailable clinical evidenceEffective local tumor controlLocal tumor controlReduced systemic toxicityIntraarterial approachStage diseaseTransarterial chemoembolizationTreatment guidelinesClinical evidenceHepatic malignanciesTumor controlSystemic toxicityTherapyScientific rationalePatientsCancerTreatmentChemoembolization